needledead1
About
Dosing 225Ac-DOTATOC throughout people using somatostatin-receptor-positive solid malignancies: 5-year follow-up involving hematological and renal toxicity.
Dosing 225Ac-DOTATOC throughout people using somatostatin-receptor-positive solid malignancies: 5-year follow-up involving hematological and renal toxicity.